CryoNet - Thu 16 Mar 2000
Message #13394
From: Olaf Henny
RAMSEY, N.J., March 15 /PRNewswire/ -- Alteon Inc. (OTC Bulletin Board: ALTN),
announced today that a new pre-clinical study of ALT-711, lead Advanced Glycosylation
End-Product ("A.G.E.") Crosslink Breaker, has been published in the March 14th issue of
the Proceedings of the National Academy of Sciences (PNAS). The article details
ALT-711's ability to reverse cardiac stiffness in aged dogs, restoring the
cardiovascular system to a state found in younger animals.
In this study, administration of ALT-711 daily for one month resulted in a 40%
reduction in age-related ventricular stiffness, or hardening. This decrease in
stiffness was accompanied by an overall improvement in cardiac function, as evidenced
by increased left ventricular end-diastolic volume, stroke volume and decreased
end-diastolic pressure.
This archive was generated by hypermail 2b29 : Thu Jul 27 2000 - 14:05:24 MDT